{
  "ticker": "CDX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02965264",
  "id": "02965264",
  "pages": 10,
  "price_sensitive": false,
  "date": "20250702",
  "time": "1641",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250702/pdf/06ldcthpvcmt8y.pdf",
  "summary": "### **Material Information Summary (CardieX Limited \u2013 Change of Director Interests)**  \n\n- **Transaction Type**: Participation in **non-renounceable pro rata Entitlement Offer** (announced 6 June 2025).  \n- **Issue Price**: **A$0.04 per share**.  \n- **Directors\u2019 Acquisitions**:  \n  - **Niall Cairns**:  \n    - Direct: 250,000 FPO  \n    - Indirect (via entities): 53.96M FPO (total across C2 Ventures, Carnethy Evergreen, Carnethy Investments).  \n  - **Craig Cooper**:  \n    - Indirect (via C2 Ventures): 45.69M FPO.  \n  - **Charlie Taylor**:  \n    - Indirect (via CW Taylor Family Trust): 208,334 FPO.  \n- **Post-Transaction Holdings**:  \n  - C2 Ventures (controlled by Cairns/Cooper): **168.47M FPO** (+45.69M).  \n- **Key Context**: Reinforces director commitment post-capital raising (likely linked to prior placement/SPP).  \n- **No Closed Period Trading**: No clearance violations.  \n\n**No other material information identified.**  \n\n*(Note: Excludes routine holdings, options, and performance rights unless directly changed by this transaction.)*",
  "usage": {
    "prompt_tokens": 3930,
    "completion_tokens": 280,
    "total_tokens": 4210,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-02T07:19:57.379715"
}